Research Paper

Predictive performance of eLIFT for liver inflammation and fibrosis in chronic liver diseases

Zongguo Yang2#, Xin Ma3#, Xinlan Zhou1#, Dan Huang1, Yanbing Wang1, Xiufen Li1, Wei Lu1, Zhanqing Zhang1###, Rongrong Ding1##

1. Department of Hepatobiliary Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
2. Department of Integrative Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
3. Department of Ultrasound, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.

#These authors have contributed equally to this work.

##Corresponding authors: Zhanqing Zhang, MD, Department of Hepatobiliary Medicine, Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Shanghai 201508, China. Tel: +8621-37990333 ext.3245; Email: doctorzzqsphc@163.com; ORCID: https://orcid.org/0000-0001-7709-9027.

Rongrong Ding, MD, Department of Hepatobiliary Medicine, Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Shanghai 201508, China. Tel: +8621-37990333 ext.3245; Email: dingrongrong@shphc.org.cn; ORCID: https://orcid.org/0000-0003-0581-9886.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

See http://ivyspring.com/terms for full terms and conditions.

Received: 2021.05.06; Accepted: 2021.08.19; Published: 2021.08.27

Abstract

Objective: The easy liver fibrosis test (eLIFT) is a novel predictor of liver fibrosis in chronic liver disease (CLD). This study aimed to evaluate the predictive value of the eLIFT for liver inflammation and fibrosis in CLD patients.

Methods: We enrolled 1125 patients with CLD who underwent liver biopsy. The predictive accuracy for liver inflammation and fibrosis of the eLIFT was assessed and compared to that of the aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis-4 score (FIB-4), and gamma-glutamyl transpeptidase-to-platelet ratio (GPR) by ROC (Receiver Operating Characteristic) analysis and decision curve analysis (DCA).

Results: The areas under the ROC curves (AUROCs) of the eLIFT for assessing liver inflammation G ≥ 2 and G ≥ 3 were 0.77 (0.75-0.80) and 0.81 (0.79-0.84), with cut-offs of 8.0 and 11.0, respectively. The AUROCs of the eLIFT for predicting fibrosis stages S ≥ 2 and S4 were 0.72 (0.70-0.76) and 0.76 (0.72-0.80), with cut-offs of 9.0 and 10.0, respectively. In discriminating G≥2 inflammation, the AUROC of the eLIFT was better than that of the FIB-4, with no difference compared with the GPR, but lower than that of the APRI. When discriminating G≥3 inflammation, the AUROC of the eLIFT was comparable to that of the APRI and GPR but superior to that of the FIB-4. There were no significant differences between the four indexes for predicting S≥2 and S4.

Conclusion: The eLIFT is a potentially useful noninvasive predictor of liver inflammation and fibrosis in patients with CLD.

Key words: eLIFT, GPR, liver fibrosis, chronic liver disease

Introduction

Chronic liver disease (CLD), of which liver fibrosis is a common consequence, is a major public health problem with high morbidity and mortality worldwide. In 2015, viral hepatitis caused 1.34 million deaths [1]. The incidence rate of alcoholic liver disease and nonalcoholic fatty liver disease is also rising [2-4]. Fibrosis progression contributed significantly to an increased risk of cirrhosis. If not properly managed, liver functional impairment, subsequent structural deformation, and haemodynamic deterioration may lead to portal hypertension-related complications and an increase in the incidence of liver cancer [5]. Therefore, the early detection of liver fibrosis is very important in the treatment of CLD to prevent irreversible damage.

At present, liver biopsy is still considered the gold standard procedure for accurately assessing liver histological scores. However, the wide clinical
application of this procedure is restricted due to its drawbacks, such as invasiveness, patient discomfort, sampling error, potential risk of complications, and interobserver variability [6,7]. Clinical practice requires simple procedures or noninvasive and simple methods to diagnose liver inflammation and fibrosis [8]. Transient elastography (TE) has been introduced as a noninvasive, highly reproducible technique for the assessment of liver fibrosis, which may reduce the need for liver biopsy [9-11]. However, some drawbacks, such as expensive equipment and lack of trained operators, limit the clinical application of TE, especially in resource-limited environments. Therefore, many studies have concentrated on the development of simple and practical serum noninvasive markers that are more accessible to the majority of the public [12].

The World Health Organization (WHO) has recommended serum biomarkers, including the aspartate aminotransferase to platelet ratio index (APRI) and four factor-based fibrosis index (FIB-4), as alternative methods for liver biopsy [13, 14]. However, the performances of the APRI and FIB-4 for the evaluation of liver fibrosis are still controversial [15, 16]. The gamma-glutamyl transpeptidase to platelet ratio (GPR) is more accurate than the APRI and FIB-4 in estimating liver fibrosis in West African cohorts with CHB (chronic hepatitis B), but it was not superior to the APRI and FIB-4 in a French cohort [14]. Other studies have also not observed advantages of the GPR [17, 18].

Based on 2503 patients with CLD, Boursier et al. [19] developed a novel panel, the easy Liver Fibrosis Test (eLIFT), which was used to diagnose liver fibrosis and cirrhosis. Compared to other blood markers, the eLIFT is easily calculated, as it was equivalent to a sum of points attributed to age, sex, GGT, AST, platelet count and prothrombin time. However, its use in the diagnosis of inflammation and fibrosis in CLD patients with different aetiologies is limited.

The aim of this study was to compare the clinical significance of the eLIFT, APRI, FIB-4, and GPR for staging liver inflammation and fibrosis in CLD patients with different aetiologies using the histopathology of liver biopsies as the reference standard.

Materials and Methods

Study Population

A total of 1125 consecutive patients with chronic liver disease who underwent percutaneous liver biopsy at Shanghai Public Health Clinical Center, Fudan University, from January 2015 to December 2019 were retrospectively studied. All the patients were > 18 years old. Inclusion criteria were diagnosis of treatment-naïve chronic viral hepatitis (hepatitis B or C), alcoholic liver disease, nonalcoholic fatty liver, or autoimmune hepatitis, and being off potential transaminase-lowing agents for at least 2 weeks prior to routine laboratory tests. The exclusion criteria were hepatocellular carcinoma, HIV coinfection, antiviral treatment history, decompensated cirrhosis, inadequate liver biopsy samples (<1.5 cm), and pregnancy.

Liver biopsy

Percutaneous liver biopsy was performed using a 16 G needle under ultrasound guidance. Liver samples with a minimum length of 1.5 cm and at least 6 complete portal tracts were considered suitable for liver histological scoring. Liver histology was analysed by two experienced pathologists who were blinded to other clinical and laboratory data and classified according to the Scheuer scoring system [20]: G 0-4 and S 0-4.

Routine laboratory parameters

Fasting blood samples were obtained within a week of liver biopsy. Platelets and other blood cells were counted using a Sysmex-XT 400i automated haematology analyser. Prothrombin time and other coagulation indexes were measured using a STAR Max automatic coagulation analyser. Alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transferase (GGT), and other serum biochemical parameters were measured using an Architectc16000 automatic biochemical analysis system.

Formulas

The formulas for the eLIFT, APRI, FIB-4, and GPR are described here. The eLIFT score is the sum of assigned values for age, sex, GGT, AST, platelet count, and prothrombin time. However, its use in the diagnosis of inflammation and fibrosis in CLD patients with different aetiologies is limited.

The aim of this study was to compare the clinical significance of the eLIFT, APRI, FIB-4, and GPR for staging liver inflammation and fibrosis in CLD patients with different aetiologies using the histopathology of liver biopsies as the reference standard.

Materials and Methods

Study Population

A total of 1125 consecutive patients with chronic liver disease who underwent percutaneous liver biopsy at Shanghai Public Health Clinical Center, Fudan University, from January 2015 to December 2019 were retrospectively studied. All the patients were > 18 years old. Inclusion criteria were diagnosis of treatment-naïve chronic viral hepatitis (hepatitis B or C), alcoholic liver disease, nonalcoholic fatty liver, or autoimmune hepatitis, and being off potential transaminase-lowing agents for at least 2 weeks prior to routine laboratory tests. The exclusion criteria were hepatocellular carcinoma, HIV coinfection, antiviral treatment history, decompensated cirrhosis, inadequate liver biopsy samples (<1.5 cm), and pregnancy.

Liver biopsy

Percutaneous liver biopsy was performed using a 16 G needle under ultrasound guidance. Liver samples with a minimum length of 1.5 cm and at least 6 complete portal tracts were considered suitable for liver histological scoring. Liver histology was analysed by two experienced pathologists who were blinded to other clinical and laboratory data and classified according to the Scheuer scoring system [20]: G 0-4 and S 0-4.

Routine laboratory parameters

Fasting blood samples were obtained within a week of liver biopsy. Platelets and other blood cells were counted using a Sysmex-XT 400i automated haematology analyser. Prothrombin time and other coagulation indexes were measured using a STAR Max automatic coagulation analyser. Alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transferase (GGT), and other serum biochemical parameters were measured using an Architectc16000 automatic biochemical analysis system.

Formulas

The formulas for the eLIFT, APRI, FIB-4, and GPR are described here. The eLIFT score is the sum of assigned values for age, sex, GGT, AST, platelet counts, and prothrombin time(%): age (years): < 40 = 0, ≥ 40 = 3; sex: female = 0, male = 1; AST (IU/L): < 35 = 0, 35-69 = 2, ≥ 70 = 4; GGT (IU/L): < 35 = 0, 35-89 = 1, ≥ 90 = 2; platelet counts (10^9/L): ≥ 250 = 0, 170-249 = 1, < 170 = 4; prothrombin time (%): ≥ 97 = 0, 84-96 = 2, < 84 = 4. The APRI is calculated as (AST (U/L)/ULN of AST)/platelet count (10^9/L) × 100. The FIB-4 is calculated as (age (years) × AST (U/L))/(platelet count (10^9/L) × (ALT (U/L)) 1/2). The GPR is calculated as (GGT (U/L)/ULN of GGT)/platelet count (10^9/L) × 100.

Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics version 26.0 (SPSS Inc., Chicago, USA) and R 4.0.2 (http://www.R-project.org). Continuous
variables are given as the median (range) and compared using the independent Mann-Whitney test. Categorical variables are given as proportions and compared by the chi-squared test. Correlations were evaluated by Spear’s correlation coefficient for continuous variables. The performances of serum models for predicting liver histological scores were assessed by receiver operating characteristic (ROC) curve analyses and area under the ROC curves (AUROCs). The Delong Z test was used to compare the AUROCs of the serum models. Decision curve analysis (DCA) was used to further evaluate predictive performance. A two-sided P<0.05 was considered statistically significant.

Results

Baseline characteristics of study patients

One thousand one hundred twenty-five patients with chronic liver disease were enrolled in our study. The baseline clinical characteristics of the study cohort are described in Table 1. Of them, the patients had a median age of 37 (30-46) years, and the majority were male (65.2%). The majority of patients suffered from chronic hepatitis B (CHB) (75.8%). The distribution of liver inflammatory activities was 585 (52.0%) patients with G0-1 and 540 (48.0%) with G2-3. The distribution of fibrosis stages was 583 (51.8%) patients with S0-1 and 542 (48.2%) with S2-4. Generally, compared with patients in G0-1, patients in G2-3 had higher ALT, AST, and GGT levels, eLIFT scores, APRI, FIB-4, and GPR; but lower platelet counts and prothrombin activities. Similar trends in these noninvasive markers were also observed in patients with fibrosis S2-4.

Serum markers and liver histological scores

The Kruskal-Wallis test showed that the eLIFT score, APRI, FIB-4, and GPR increased significantly in those with moderate to severe liver inflammation (G2-3) compared to G0-1 patients (Figure 1a-d). In regard to liver fibrosis, the same was true (Figure 1e-f). In other words, higher mode scores were seen with increasing liver histological scores. Spearman’s correlation analysis showed that the eLIFT score (r = 0.517), APRI (r = 0.577), FIB-4 (r = 0.422), and GPR (r = 0.556) were significantly correlated with liver inflammatory activities. For liver fibrosis, the eLIFT score (r = 0.506), APRI (r = 0.487), FIB-4 (r = 0.395), and GPR (r = 0.507) were significantly correlated with fibrosis stage (Table 2).

### Table 1. Clinical characteristics of the study patients

| Variables                        | Total (n = 1125) | Inflammatory activity | Fibrosis stage |
|----------------------------------|-----------------|-----------------------|----------------|
|                                  |                 | G0-1 (n = 585) | G2-4 (n = 540) | P value |
|                                  |                 | G0-1 (n = 585) | G2-4 (n = 540) | P value |
| Age, years                       | 37 (30-46)      | 37 (30-46)       | 36 (29-46)     | 0.196  | 37 (30-46)       | 36 (30-46)     | 0.544  |
| Male, n (%)                      | 734 (65.2)      | 392 (62.0)       | 342 (69.4)     | 0.010  | 351 (61.4)       | 383 (69.3)     | 0.005  |
| Etiology of liver disease        |                 |                     |                |        |
| HBV infection, n (%)             | 853 (75.8%)     | 440 (75.2%)      | 413 (76.5%)    | 0.620  | 434 (74.4%)      | 419 (77.3%)    | 0.262  |
| HCV infection, n (%)             | 32 (2.8)        | 13 (2.2%)        | 19 (3.5%)      | 0.191  | 13 (2.2%)        | 19 (3.5%)      | 0.198  |
| Non-alcoholic fatty liver disease, n (%) | 144 (12.8%) | 101 (17.3%)     | 43 (8.0%)      | <0.001 | 104 (17.8%) | 40 (7.4%)      | <0.001 |
| Alcoholic fatty liver disease, n (%) | 43 (3.8%)  | 13 (2.2%)        | 30 (5.6%)      | 0.004  | 14 (2.4%)        | 29 (5.4%)      | 0.010  |
| Autoimmune liver disease, n (%)  | 53 (4.7%)       | 18 (3.1%)        | 35 (6.5%)      | 0.007  | 18 (3.1%)        | 35 (6.5%)      | 0.008  |
| Serological parameters           |                 |                     |                |        |
| ALT, U/L                         | 90.9 (29.1-133.5) | 38.0 (22.0-78.0) | 101.0 (52.0-262.8) | <0.001 | 41.0 (22.0-87.0) | 85.0 (41.0-185.0) | <0.001 |
| AST, U/L                         | 40.1 (25.0-83.5) | 28.0 (21.0-44.0) | 68.5 (40.0-141.0) | <0.001 | 29.0 (21.0-49.0) | 57.0 (33.0-115.0) | <0.001 |
| ALP, U/L                         | 76.0 (63.0-97.0) | 70.0 (57.0-84.0) | 88.0 (72.0-113.0) | <0.001 | 71.0 (58.0-87.0) | 84.0 (68.0-109.0) | <0.001 |
| GGT, U/L                         | 35.0 (19.0-78.0) | 24.0 (16.0-41.0) | 66.0 (35.0-118.5) | <0.001 | 24.0 (16.0-45.0) | 57.0 (29.0-106.3) | <0.001 |
| TBil, µmol/L                     | 14.0 (10.0-19.8) | 12.3 (9.3-16.7) | 16.7 (11.4-25.0) | <0.001 | 12.3 (9.3-16.8) | 15.9 (11.0-24.0) | <0.001 |
| Albumin, g/L                     | 42.3 (39.5-44.7) | 43.1 (40.9-45.8) | 40.8 (37.9-43.5) | <0.001 | 43.1 (41.0-45.7) | 41.0 (38.1-43.7) | <0.001 |
| Globulin, g/L                    | 28.0 (25.0-31.0) | 27.0 (24.0-30.0) | 29.0 (26.0-32.0) | <0.001 | 27.0 (24.0-30.0) | 29.0 (26.0-32.0) | <0.001 |
| Platelet, ×10^12/L               | 160 (127-196)   | 172 (142-208)    | 144 (105-179)   | <0.001 | 178 (149-210)    | 142 (108-176)   | <0.001 |
| Prothrombin time (s)             | 43 (85-102)     | 96 (88-104)      | 90 (80-99)      | <0.001 | 98 (90-105)      | 89 (80-97)      | <0.001 |

**Table 2. Correlation between the noninvasive indexes and liver pathology score**

| Indexes | Inflammatory activity r | P value | Fibrosis stage r | P value |
|---------|-------------------------|---------|----------------|---------|
| eLIFT   | 0.517                   | <0.001  | 0.506          | <0.001  |
| APRI    | 0.577                   | <0.001  | 0.487          | <0.001  |
| FIB-4   | 0.422                   | <0.001  | 0.395          | <0.001  |
| GPR     | 0.556                   | <0.001  | 0.507          | <0.001  |

*HBV, hepatitis B virus; HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; TBil, total bilirubin*
Performances of serum markers in the evaluation of liver inflammation

The ROC curves of the eLIFT score, APRI, FIB-4, and GPR for predicting liver inflammation in all patients and in CHB patients are shown in Figure 2. In discriminating G≥2 inflammation, the AUROC of the eLIFT score was better than that of the FIB-4 (0.77 vs 0.72, respectively), with no difference compared with the GPR (0.77 vs 0.80, respectively), but lower than that of the APRI (0.77 vs 0.82, respectively). The optimal cut-off values for predicting G≥2 were 8.0 for the eLIFT score, 0.68 for the APRI, 1.48 for the FIB-4, and 0.58 for the GPR. When discriminating G≥3 inflammation, the AUROC of the eLIFT score was comparable to that of the APRI and GPR but superior to that of the FIB-4 (0.81, 0.76, and 0.83, respectively) (Table 3).

Moreover, to investigate the influence of aetiology on the predictive performance of liver pathological scores, we further performed a subgroup analysis in the 853 enrolled CHB patients. In discriminating G≥2, the AUROCs of eLIFT, APRI, FIB-4, and GPR in CHB patients were 0.78, 0.83, 0.73, and 0.82, respectively. In discriminating G≥3, the AUROCs of the eLIFT score, APRI, FIB-4, and GPR were 0.81, 0.81, 0.76, and 0.84, respectively. Similarly, the AUROC of the eLIFT score for diagnosing liver inflammation was superior to that of the FIB-4 but lower than that of the APRI and GPR in CHB patients (Table 4).

Performances of serum markers in the evaluation of liver fibrosis

The ROC curves of the eLIFT score, APRI, FIB-4, and GPR for predicting liver inflammation in all patients and in CHB patients are shown in Figure 3. In discriminating S≥2 liver fibrosis, the AUROCs of the eLIFT score, APRI, FIB-4, and GPR were 0.76, 0.72, 0.75, and 0.77, respectively. The optimal cut-off values for predicting S≥2 were 9.0 for the eLIFT score, 0.76 for the APRI, 1.57 for the FIB-4, and 0.55 for the GPR. When discriminating S4, the AUROCs of the eLIFT score, APRI, FIB-4, and GPR were 0.76, 0.72, 0.75, and 0.77, respectively. The optimal cut-off values for

Table 3. Predictive performance of serological indexes for assessing liver inflammatory in all patients (N = 1125)

|       | AUROC (95%CI) | P value | Cut-off | Se (%) | Sp (%) | PPV (%) | NPV (%) | Accuracy (%) | *P value |
|-------|--------------|---------|---------|--------|--------|---------|---------|--------------|----------|
| eLIFT |              |         |         |        |        |         |         |              |          |
| G ≥ 2 | 0.77 (0.75-0.80) | <0.0001 | 8.0     | 72.1   | 66.8   | 65.5   | 73.1   | 69.2         | --       |
| G ≥ 3 | 0.81 (0.79-0.84) | <0.0001 | 11.0    | 63.3   | 85.2   | 52.4   | 90.0   | 67.5         | --       |
| APRI  |              |         |         |        |        |         |         |              |          |
| G ≥ 2 | 0.82 (0.80-0.84) | <0.0001 | 0.68    | 79.3   | 70.9   | 68.0   | 81.5   | 74.6         | 0.0001   |
| G ≥ 3 | 0.81 (0.78-0.83) | <0.0001 | 0.78    | 87.1   | 63.7   | 35.5   | 95.6   | 65.3         | 0.798    |
| FIB-4 |              |         |         |        |        |         |         |              |          |
| G ≥ 2 | 0.72 (0.69-0.75) | <0.0001 | 1.48    | 61.5   | 72.3   | 63.4   | 70.6   | 54.9         | <0.0001  |
| G ≥ 3 | 0.76 (0.73-0.79) | <0.0001 | 1.66    | 72.4   | 71.3   | 36.7   | 91.8   | 43.0         | 0.0001   |
| GPR   |              |         |         |        |        |         |         |              |          |
| G ≥ 2 | 0.80 (0.77-0.82) | <0.0001 | 0.58    | 74.2   | 75.6   | 70.4   | 79.0   | 75.0         | 0.052    |
| G ≥ 3 | 0.83 (0.81-0.85) | <0.0001 | 0.61    | 90.5   | 65.7   | 37.7   | 96.8   | 69.7         | 0.225    |

AUROC, area under ROC; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value.

* Compared with eLIFT
predicting S4 were 10.0 for the eLIFT score, 0.85 for the APRI, 1.66 for the FIB-4, and 0.82 for the GPR. Interestingly, there were no significant differences among the four indexes for predicting S≥2 and S4 (Table 5).

Figure 2. ROC comparison of eLIFT, APRI, FIB-4, and GPR for predicting liver inflammation. (A) ROC comparison for predicting G ≥ 2 in all patients; (B) ROC comparison for predicting G ≥ 3 in all patients; (C) ROC comparison for predicting G ≥ 2 in CHB patients; (D) ROC comparison for predicting G ≥ 3 in CHB patients.

Table 4. Predictive performance of serological indexes for assessing liver inflammatory in CHB patients (N = 853)

| Index | AUROC (95%CI) | P value | Cut-off | Se (%) | Sp (%) | PPV (%) | NPV (%) | Accuracy (%) | *P value |
|-------|--------------|---------|---------|--------|--------|---------|---------|--------------|----------|
| eLIFT |              |         |         |        |        |         |         |              |          |
| G ≥ 2 | 0.78 (0.75-0.80) | <0.0001 | 8.0     | 71.1   | 69.8   | 70.5    | 70.3    | 66.9         | --       |
| G ≥ 3 | 0.81 (0.78-0.84) | <0.0001 | 9.0     | 79.6   | 69.7   | 44.2    | 91.9    | 75.0         | --       |
| APRI  |              |         |         |        |        |         |         |              |          |
| G ≥ 2 | 0.83 (0.80-0.85) | <0.0001 | 0.55    | 85.9   | 65.1   | 68.8    | 83.7    | 74.7         | 0.001    |
| G ≥ 3 | 0.81 (0.78-0.84) | <0.0001 | 1.04    | 75.7   | 75.3   | 45.2    | 92.0    | 75.3         | 0.898    |
| FIB-4 |              |         |         |        |        |         |         |              |          |
| G ≥ 2 | 0.73 (0.69-0.76) | <0.0001 | 1.34    | 66.5   | 69.8   | 66.3    | 69.9    | 67.9         | < 0.001  |
| G ≥ 3 | 0.76 (0.73-0.80) | <0.0001 | 1.66    | 70.7   | 73.4   | 41.7    | 90.3    | 72.8         | 0.001    |
| GPR   |              |         |         |        |        |         |         |              |          |
| G ≥ 2 | 0.82 (0.80-0.85) | <0.0001 | 0.55    | 74.9   | 79.3   | 76.5    | 77.9    | 77.3         | 0.004    |
| G ≥ 3 | 0.84 (0.82-0.87) | <0.0001 | 0.61    | 89.5   | 69.9   | 44.5    | 96.1    | 74.0         | 0.038    |

AUROC, area under ROC; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value.

* Compared with eLIFT
Figure 3. ROC comparison of eLIFT, APRI, FIB-4, and GPR for predicting liver fibrosis. (A) ROC comparison for predicting S ≥ 2 in all patients; (B) ROC comparison for predicting S4 in all patients; (C) ROC comparison for predicting S ≥ 2 in CHB patients; (D) ROC comparison for predicting S4 in CHB patients.

Table 5. Predictive performance of serological indexes for assessing liver fibrosis in all patients (N = 1125)

|       | AUROC (95%CI) | P value | Cut-off | Se (%) | Sp (%) | PPV (%) | NPV (%) | Accuracy | *P value |
|-------|---------------|---------|---------|--------|--------|---------|---------|----------|----------|
| eLIFT |               |         |         |        |        |         |         |          |          |
| S ≥ 2 | 0.72 (0.70-0.76) | <0.0001 | 9.0     | 60.6   | 78.7   | 76.8    | 63.1    | 62.7     |          |
| S4    | 0.76 (0.72-0.80) | <0.0001 | 10.0    | 72.5   | 78.3   | 45.7    | 91.8    | 74.3     | 0.448    |
| APRI  |               |         |         |        |        |         |         |          |          |
| S ≥ 2 | 0.70 (0.66-0.74) | <0.0001 | 0.76    | 67.7   | 73.9   | 71.5    | 70.4    | 70.1     | 0.448    |
| S4    | 0.72 (0.67-0.75) | <0.0001 | 0.85    | 76.8   | 66.3   | 34.0    | 92.7    | 68.3     | 0.168    |
| FIB-4 |               |         |         |        |        |         |         |          |          |
| S ≥ 2 | 0.70 (0.65-0.74) | <0.0001 | 1.57    | 55.3   | 75.4   | 68.5    | 63.6    | 65.5     | 0.359    |
| S4    | 0.75 (0.71-0.79) | <0.0001 | 1.66    | 72.5   | 71.0   | 36.1    | 92.0    | 65.5     | 0.883    |
| GPR   |               |         |         |        |        |         |         |          |          |
| S ≥ 2 | 0.75 (0.71-0.79) | <0.0001 | 0.55    | 71.8   | 72.9   | 71.9    | 72.8    | 72.4     | 0.272    |
| S4    | 0.77 (0.73-0.80) | <0.0001 | 0.82    | 76.8   | 74.2   | 40.2    | 93.4    | 69.4     | 0.718    |

AUROC, area under ROC; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value.

* Compared with eLIFT

In discriminating S≥2, the AUROCs of the eLIFT score, APRI, FIB-4, and GPR in CHB patients were 0.78, 0.76, 0.70, and 0.78, respectively. In discriminating S4, the AUROCs of the eLIFT score, APRI, FIB-4, and GPR were 0.76, 0.72, 0.75, and 0.77, respectively. Consistent with the results of the study in all patients, the eLIFT score was comparable to the APRI and GPR in predicting S≥2 and S4 in CHB patients (Table 6).
Table 6. Predictive performance of serological indexes for assessing liver fibrosis in CHB patients (N = 853)

|       | AUROC (95%CI) | P value | Cut-off | Se (%) | Sp (%) | PPV (%) | NPV (%) | Accuracy | *P value |
|-------|---------------|---------|---------|--------|--------|---------|---------|----------|----------|
| eLIFT |               |         |         |        |        |         |         |          |          |
| S ≥ 2 | 0.78 (0.75-0.81) | <0.0001 | 9.0     | 60.1   | 81.9   | 81.0    | 61.5    | 66.2     |          |
| S4    | 0.76 (0.72-0.80) | <0.0001 | 10.0    | 80.5   | 68.6   | 40.5    | 93.0    | 66.8     |          |
| APRI  |               |         |         |        |        |         |         |          |          |
| S ≥ 2 | 0.76 (0.73-0.79) | <0.0001 | 0.76    | 68.6   | 75.9   | 73.4    | 69.7    | 71.7     | 0.398    |
| S4    | 0.72 (0.67-0.75) | <0.0001 | 0.85    | 74.4   | 65.5   | 33.9    | 91.5    | 66.7     | 0.168    |
| FIB-4 |               |         |         |        |        |         |         |          |          |
| S ≥ 2 | 0.70 (0.67-0.73) | <0.0001 | 1.48    | 56.3   | 75.9   | 71.2    | 62.1    | 65.3     | <0.0001  |
| S4    | 0.75 (0.71-0.79) | <0.0001 | 1.65    | 70.1   | 71.8   | 37.2    | 91.0    | 71.4     | 0.883    |
| GPR   |               |         |         |        |        |         |         |          |          |
| S ≥ 2 | 0.78 (0.75-0.81) | <0.0001 | 0.55    | 69.0   | 78.3   | 77.1    | 70.4    | 73.5     | 0.992    |
| S4    | 0.77 (0.73-0.80) | <0.0001 | 0.67    | 81.7   | 70.0   | 39.3    | 94.1    | 72.1     | 0.718    |

AUROC, area under ROC; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value.

* Compared with eLIFT

DCA for clinical utility of the eLIFT

We conducted DCA to further investigate the clinical application value of the eLIFT in predicting liver inflammation and fibrosis. DCA revealed that from a threshold probability of 10%-80%, application of the eLIFT to predict liver inflammation G≥3 in all patients and CHB patients was beneficial (Figure 4). Similarly, DCA also demonstrated that from a threshold probability of 10%-80%, application of the eLIFT to predict S≥2 and S4 liver fibrosis risk increased the benefit considerably more than the other three scores in all patients and in CHB patients (Figure 5).
Discussion

In this retrospective cohort of CLD patients who underwent liver fibrosis, we validated the performances of the eLIFT, APRI, FIB-4 and GPR in diagnosing liver inflammation and fibrosis. Our study suggested that these markers might be potentially useful in predicting liver inflammation and fibrosis. The eLIFT and GPR might be useful serum indexes for evaluating the histological changes of CLD patients. The APRI, GPR, and eLIFT were superior to the FIB-4 for diagnosing liver inflammation. Similarly, the eLIFT and GPR were superior to the APRI and FIB-4 for diagnosing liver fibrosis.

The eLIFT is a new, user-friendly, rapid fibrosis test that can be used by all physicians who manage CLD patients in daily clinical practice, regardless of whether they specialize in hepatology, as it is based on the parameters usually evaluated in CLD [19]. The eLIFT had two main advantages. First, compared with the APRI and FIB-4, which require a computer to calculate, the eLIFT score can be calculated very easily, which makes the eLIFT more convenient to use than the APRI and FIB-4 in clinical practice. Second, the eLIFT had fewer false positive results in 1251 CLD patients, so it was more suitable for screening [19]. In this study, we confirmed the good clinical application value of the eLIFT. These results were consistent with previous studies [19, 21]. The performance of the eLIFT was good for diagnosing liver inflammation, with AUROCs of 0.71 and 0.81 for G≥2 and G≥3, respectively. As expected, the performance of the eLIFT was also satisfactory for diagnosing liver fibrosis, with AUROCs of 0.73 and 0.76 for S≥2 and S4, respectively. Wang et al. [21] proposed that the eLIFT had similar diagnostic values for advanced fibrosis compared to more complex tools, such as the APRI, FIB-4, GPR, and RPR, in chronic hepatitis B (CHB) patients. However, in another larger study that included 747 CHB patients, the AUROC of the eLIFT was lower than those of the APRI and FIB-4 for diagnosing significant liver fibrosis and cirrhosis [22].
The GPR is a new noninvasive index for diagnosing liver fibrosis in CHB patients, although its diagnostic value is still controversial [17,23,24]. A meta-analysis based on 10 studies reported that the AUROCs of the GPR for assessing significant fibrosis, advanced fibrosis, and cirrhosis were 0.73, 0.78, and 0.80, respectively [25]. In our study, we found that the GPR was also satisfactory not only for the diagnosis of liver fibrosis but also for the diagnosis of liver inflammation. The GPR was comparable to the APRI but superior to the FIB-4 for predicting liver inflammation. The GPR exhibited AUROCs of 0.80 for G≥2, with an optimal cut-off of 0.58. The AUROC of the GPR increased to 0.83 when used to diagnose G≥3, with an optimal cut-off of 0.61. These results are consistent with previous studies [26, 27]. Regarding liver fibrosis, the GPR was superior to the APRI and FIB-4 for diagnosing S≥2 and S4. The AUROCs of the GPR were 0.75 for S≥2 and 0.76 for S4. The GPR cut-off values (0.55 for S≥2, 0.82 for S4) were higher than those obtained by Lemoine [28] (0.32 for F≥2, 0.56 for F4).

One limitation of this study was that it was a single-centre retrospective study; thus, the results should be further confirmed in multicentre prospective studies with large-scale populations. Furthermore, since there were insufficient clinical data from FibroScan, we could not evaluate the performance of FibroScan for the diagnosis of liver inflammation and fibrosis.

In conclusion, the present study demonstrates that the eLIFT is a potentially useful noninvasive predictor of liver inflammation and fibrosis in patients with CLD. Although the eLIFT had similar diagnostic power to the liver histopathological score, compared with the APRI and GPR, in CLD patients, it had the advantage of easy implementation with wide clinical utility.

Acknowledgements

Author Contributions

YZG, MX, and ZXL designed the study and wrote the manuscript; HD, LXF and WYB collected clinical data and analyzed data; YL and LW were involved in critical revision of the paper. ZZQ and DRR approved the final manuscript. All authors have read and approved the manuscript.

Funding source

This work was supported by the “13th Five-year” National Science and Technology Major Project of China (2017ZX10203202) and Shanghai Municipal Hospital of Joint Research Projects in Emerging Cutting-Edge Technology (SHDC12016237).

Ethical approval

The study protocol and informed consent documents were reviewed and approved by the Ethics Committee of Shanghai Public Health Clinical Center, Fudan University. All these chronic hepatitis patients provided written informed consent before participating in this study.

Data availability

Datasets of the current study are available from the corresponding authors on reasonable request.

Competing Interests

The authors have declared that no competing interest exists.

References

1. [Internet] World Health Organization (WHO). Global hepatitis report. Available at: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ [Accessed 31 May 2018].
2. Fan JG. Epidemiology of chronic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013;28 (Suppl 1):S11-S17.
3. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148:547-555.
4. Araujo AR, Rosso N, Bedogni G, et al. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 2018;38 (Suppl 1): S47-S51.
5. Pungpapong S, Kim WR, Potterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clinic Proceedings. 2007; 82:967-975.
6. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20(1 Pt 1):15-20.
7. Regev A, Berho M, Jeffers LJ, et al. Sampling error and interobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614-2618.
8. Zhang Z, Wang G, Kang K, et al. The diagnostic accuracy and clinical utility of three noninvasive models for predicting Liver Fibrosis in patients with HBV infection. PLoS One. 2016;11(4):e0152757.
9. Dong H, Xu C, Zhou W, et al. The combination of 5 serum markers compared to FibroScan to predict significant liver fibrosis in patients with chronic hepatitis B virus. Clin Chim Acta. 2018;483:145-152.
10. Huang R, Jiang N, Yang R, et al. Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B. Exp Ther Med. 2016;11:1673-1677.
11. Seo YS, Kim MY, Kim SU, et al. Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. Liver Int. 2015;35:2246-2255.
12. Dong QX, Wu Z, Zhao H, Wang QG, China Hep BRFARG. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in Chinese hepatitis B patients. J Viral Hepat. 2019;26:297-307.
13. In: Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. edn. Geneva; 2015.
14. Dong M, Wu J, Yu X, et al. Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients. Liver Int. 2018; 38:1562-1570.
15. Wu X, Cai B, Su Z, et al. Aspartate transaminase to platelet ratio index and gamma-glutamyl transpeptidase-to-platelet ratio outweigh fibrosis index based on four factors and red cell distribution width-platelet ratio in diagnosing liver fibrosis and inflammation in chronic hepatitis B. J Clin Lab Anal. 2018;32:e22341.
16. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61:292-302.
17. Li Q, Li W, Huang Y, Chen L. The gamma-glutamyl transpeptidase-to-platelet ratio predicts liver fibrosis and cirrhosis in HBeAg-positive chronic HBV infection patients with high HBV DNA and normal or mildly elevated alanine transaminase levels in China. J Viral Hepat. 2016;23:912-919.
18. Zhang W, Sun M, Chen G, et al. Reassessment of gamma-glutamyl transpeptidase to platelet ratio (GPR): a large-sample, dynamic study based on liver biopsy in a Chinese population with chronic hepatitis B virus (HBV) infection. Gut. 2018; 67:989-991.
19. Boursier J, de Ledinghen V, Leroy V, et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol. 2017;66:1158-1165.
20. Scheuer PJ: Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372-374.
21. Wang J, Chen Z, Yan XM, et al. The Easy Liver Fibrosis Test (eLIFT) for predicting advanced liver fibrosis in patients with chronic hepatitis B. Discov Med. 2019;28:149-158.
22. Li Q, Lu C, Li W, et al. Evaluation of eLIFT for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis B virus infection. Sci Rep. 2017;7:5429.
23. Ren T, Wang H, Wu R, Niu J. Gamma-Glutamyl Transpeptidase-to-platelet ratio predicts significant Liver Fibrosis of chronic hepatitis B patients in China. Gastroenterol Res Pract. 2017;2017:7089702.
24. Wang RQ, Zhang QS, Zhao SX, et al. Gamma-glutamyl transpeptidase to platelet ratio index is a good noninvasive biomarker for predicting liver fibrosis in Chinese chronic hepatitis B patients. J Int Med Res. 2016;44:1302-1313.
25. Lian MJ, Zhang JQ, Chen SD, et al. Diagnostic accuracy of gamma-glutamyl transpeptidase-to-platelet ratio for predicting hepatitis B-related fibrosis: a meta-analysis. Eur J Gastroenterol Hepatol. 2019;31:599-606.
26. Wu X, Cai B, Su Z, et al. Aspartate transaminase to platelet ratio index and gamma-glutamyl transpeptidase-to-platelet ratio out weigh fibrosis index based on four factors and red cell distribution width-platelet ratio in diagnosing liver fibrosis and inflammation in chronic hepatitis B. J Clin Lab Anal. 2018;32:e22341.
27. Wang LM, Li J, Yang K, et al. Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis of chronic hepatitis B virus-infected patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels. Medicine (Baltimore). 2020;99:e20548.
28. Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut. 2016;65:1369-1376.